HC Wainwright & Co. Reiterates Buy on Apellis Pharmaceuticals, Maintains $100 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao reiterates a Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) and maintains a $100 price target.
June 13, 2023 | 10:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apellis Pharmaceuticals receives a reiterated Buy rating and a maintained $100 price target from HC Wainwright & Co. analyst Douglas Tsao.
The reiterated Buy rating and maintained $100 price target by HC Wainwright & Co. analyst Douglas Tsao indicates a positive outlook for Apellis Pharmaceuticals. This news is likely to have a positive short-term impact on the stock price as it reaffirms the analyst's confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100